Results from a phase III clinical study published online yesterday in the European Journal of Neurology Early View showed that about half of all people with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to standard anti-spasticity therapy, find that adding Sativex® Oromucosal Spray (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), to their existing medication can improve the debilitating symptoms of spasticity associated with MS.1
The primary efficacy endpoint was the change in a validated, 10 point (0-10) self-reported spasticity numerical rating scale (NRS) from the point of randomisation to the end of the treatment.1 Sativex® was shown to provide significant improvement, compared to placebo, in the NRS spasticity score, spasm frequency and sleep disturbance related to spasticity.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814